Scribe Therapeutics, a biotech company focused on gene-editing technologies for cardiovascular diseases, successfully launched its initial public offering (IPO) on July 24, 2026. The Eli Lilly-backed firm aimed to raise $100.1 million, signaling continued investor interest in high-growth tech and biotech enterprises.